The Washington Times (www.washingtontimes.com) published an article on April 21, 2017, on the topic of marijuana, the world’s most popular illicit drug.
It cited the research on a growing body of evidence that cannabis may be a potentially useful treatment for a range of conditions, including anxiety, PTSD, schizophrenia, and pain.
In addition, the article noted that cannabis has been shown to reduce pain and anxiety in people with multiple sclerosis.
The article did not say how many studies were being conducted, but said that “many are now underway.”
It did not mention which states have legalized marijuana for medical use.
But in addition to the article on cannabis and its possible benefits, the Times also cited research from the U.S. National Institute on Drug Abuse that found that “a marijuana use disorder, known as MJD, was associated with significant increases in symptoms of PTSD, depression, and anxiety.”
It said that research shows that “cannabinoids act as pain medications and are also effective for relieving symptoms of posttraumatic stress disorder and anxiety, as well as for relievers of pain associated with cancer.” “
Studies are also showing that cannabinoids, the main component in marijuana, can be used to treat many types of pain, including fibromyalgia and other pain conditions,” the Times said.
It said that research shows that “cannabinoids act as pain medications and are also effective for relieving symptoms of posttraumatic stress disorder and anxiety, as well as for relievers of pain associated with cancer.”
In addition to being used for relief from pain, cannabinoids also have been found to reduce anxiety.
And studies are showing that they may be useful for treating other illnesses, such as multiple sclerosis and Parkinson’s disease.
For example, a study published in March 2018 in the journal Neuropsychopharmacology found that THC, a compound found in marijuana that is believed to relieve some of the symptoms of some diseases, “may also reduce anxiety, reduce stress, and help relieve depression.”
The study found that using marijuana was not only useful for the treatment of anxiety, but it may also have therapeutic benefits for other ailments.
It noted that THC also appears to be effective for treating PTSD and anxiety.
A study published this past May in the Journal of Neurotherapeutics, also published in the medical journal, found that cannabinoids “may offer a novel therapeutic approach for treating anxiety and other disorders that have a biological basis.”
The findings were based on the use in a clinical trial of a cannabinoid oil, THC, that was administered intravenously and in a sham condition.
THC is a chemical compound with the chemical structure of the marijuana plant.
The study, led by David Nussbaum of the University of California, Berkeley, found a “small but significant” reduction in anxiety symptoms in people given THC compared to a placebo.
The researchers also found that people who received THC had less anxiety than those who received placebo.
In another study published last year in the Proceedings of the National Academy of Sciences, researchers at the University College London found that marijuana, or cannabidiol, “can be used in a manner similar to traditional cannabis to treat some forms of anxiety.”
A study from the University and Yale universities last year found that the compound, which is found in the plant’s seeds, “cannabidivarin,” is “effective in reducing anxiety in patients with moderate to severe anxiety disorders and depression.”
A research study published earlier this year in Psychopharmacologia found that cannabichromene, another chemical compound found within the cannabis plant, can “promote brain health and well-being.”
The researchers used cannabigerol, a chemical component of THC, to study the effects of the drug on brain activity in rats.
They found that it was effective in reducing the activity of the reward-seeking system, and “enhanced the function of brain-derived neurotrophic factor (BDNF), which has been found in many parts of the brain to be important in regulating mood and stress responses.”
The research team, led the by Dr. Andrew Hsu of the Department of Pharmacology and Pharmacology at the Yale School of Medicine, said that while the study was not yet conclusive, “we suggest that CBD may have therapeutic potential for treating major depression.”
“Cannabigerolic acid has shown promising safety and efficacy in human trials for depression,” Dr. Hsu said.
“In addition to helping to reduce depression, CBD could help relieve anxiety in some patients with PTSD, and other chronic disorders that include anxiety, depression and obsessive-compulsive disorder.”
The American Academy of Neurology published an editorial in 2016 in which it said that CBD was “an effective therapeutic agent for the management of PTSD.”
The statement said that it “does not appear that any cannabinoids have the potential to be safe and effective as pharmacological treatments for PTSD.”
But it noted that the American Academy does not support marijuana for recreational use.
The American Psychological Association (APA) said in a statement that